#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Extracellular vesicles ( EVs ) are cell-derived membrane vesicles that represent an endogenous mechanism for intercellular communication .
3-1	17-30	Extracellular	object[3]	new[3]	_	_
3-2	31-39	vesicles	object[3]	new[3]	_	_
3-3	40-41	(	_	_	_	_
3-4	42-45	EVs	abstract	new	coref	4-1
3-5	46-47	)	_	_	_	_
3-6	48-51	are	_	_	_	_
3-7	52-64	cell-derived	_	_	_	_
3-8	65-73	membrane	object|object[6]	new|new[6]	coref|coref|coref|coref	4-8[12_6]|4-53|4-8[12_6]|4-53
3-9	74-82	vesicles	object[6]	new[6]	_	_
3-10	83-87	that	_	_	_	_
3-11	88-97	represent	_	_	_	_
3-12	98-100	an	abstract[7]	new[7]	_	_
3-13	101-111	endogenous	abstract[7]	new[7]	_	_
3-14	112-121	mechanism	abstract[7]	new[7]	_	_
3-15	122-125	for	abstract[7]	new[7]	_	_
3-16	126-139	intercellular	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-17	140-153	communication	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-18	154-155	.	_	_	_	_

#Text=EVs can be classified in exosomes , nano-sized vesicles ( with a diameter in the range of 30 to 120 nm ) , that originate from the cell endocytic compartment through the formation of multivesicular bodies ( MVB ) , microvesicles , with a diameter up to 1 μm released by cell membrane budding , and apoptotic bodies , with a dimension similar to platelets , derived from blebbing of dying cells .
4-1	156-159	EVs	object	giv	coref	6-8[45_0]
4-2	160-163	can	_	_	_	_
4-3	164-166	be	_	_	_	_
4-4	167-177	classified	_	_	_	_
4-5	178-180	in	_	_	_	_
4-6	181-189	exosomes	object|object[11]	new|new[11]	coref|coref|coref|coref	6-14[46_0]|6-14[47_11]|6-14[46_0]|6-14[47_11]
4-7	190-191	,	object[11]	new[11]	_	_
4-8	192-202	nano-sized	object[11]|object[12]	new[11]|giv[12]	_	_
4-9	203-211	vesicles	object[11]|object[12]	new[11]|giv[12]	_	_
4-10	212-213	(	object[11]|object[12]	new[11]|giv[12]	_	_
4-11	214-218	with	object[11]|object[12]	new[11]|giv[12]	_	_
4-12	219-220	a	object[11]|object[12]|quantity[13]	new[11]|giv[12]|new[13]	coref	4-44[24_13]
4-13	221-229	diameter	object[11]|object[12]|quantity[13]	new[11]|giv[12]|new[13]	_	_
4-14	230-232	in	object[11]|object[12]|quantity[13]	new[11]|giv[12]|new[13]	_	_
4-15	233-236	the	object[11]|object[12]|quantity[13]|abstract[14]	new[11]|giv[12]|new[13]|new[14]	_	_
4-16	237-242	range	object[11]|object[12]|quantity[13]|abstract[14]	new[11]|giv[12]|new[13]|new[14]	_	_
4-17	243-245	of	object[11]|object[12]|quantity[13]|abstract[14]	new[11]|giv[12]|new[13]|new[14]	_	_
4-18	246-248	30	object[11]|object[12]|quantity[13]|abstract[14]|quantity	new[11]|giv[12]|new[13]|new[14]|new	_	_
4-19	249-251	to	object[11]|object[12]|quantity[13]|abstract[14]	new[11]|giv[12]|new[13]|new[14]	_	_
4-20	252-255	120	object[11]|object[12]|quantity[13]|abstract[14]|quantity[16]	new[11]|giv[12]|new[13]|new[14]|new[16]	_	_
4-21	256-258	nm	object[11]|object[12]|quantity[13]|abstract[14]|quantity[16]	new[11]|giv[12]|new[13]|new[14]|new[16]	_	_
4-22	259-260	)	object[11]|object[12]	new[11]|giv[12]	_	_
4-23	261-262	,	_	_	_	_
4-24	263-267	that	_	_	_	_
4-25	268-277	originate	_	_	_	_
4-26	278-282	from	_	_	_	_
4-27	283-286	the	place[19]	new[19]	_	_
4-28	287-291	cell	object|place[19]	new|new[19]	coref	14-24
4-29	292-301	endocytic	object|place[19]	new|new[19]	_	_
4-30	302-313	compartment	place[19]	new[19]	_	_
4-31	314-321	through	_	_	_	_
4-32	322-325	the	event[20]	new[20]	_	_
4-33	326-335	formation	event[20]	new[20]	_	_
4-34	336-338	of	event[20]	new[20]	_	_
4-35	339-353	multivesicular	event[20]|object[21]	new[20]|new[21]	appos	4-38[0_21]
4-36	354-360	bodies	event[20]|object[21]	new[20]|new[21]	_	_
4-37	361-362	(	_	_	_	_
4-38	363-366	MVB	object	giv	coref	4-57[28_0]
4-39	367-368	)	_	_	_	_
4-40	369-370	,	_	_	_	_
4-41	371-384	microvesicles	object[23]	new[23]	coref	6-17[0_23]
4-42	385-386	,	object[23]	new[23]	_	_
4-43	387-391	with	object[23]	new[23]	_	_
4-44	392-393	a	object[23]|quantity[24]	new[23]|giv[24]	_	_
4-45	394-402	diameter	object[23]|quantity[24]	new[23]|giv[24]	_	_
4-46	403-405	up	object[23]|quantity[24]	new[23]|giv[24]	_	_
4-47	406-408	to	object[23]|quantity[24]	new[23]|giv[24]	_	_
4-48	409-410	1	object[23]|quantity[24]|quantity[25]	new[23]|giv[24]|new[25]	_	_
4-49	411-413	μm	object[23]|quantity[24]|quantity[25]	new[23]|giv[24]|new[25]	_	_
4-50	414-422	released	_	_	_	_
4-51	423-425	by	_	_	_	_
4-52	426-430	cell	object[27]	new[27]	_	_
4-53	431-439	membrane	object|object[27]	giv|new[27]	coref	11-14[91_0]
4-54	440-447	budding	object[27]	new[27]	_	_
4-55	448-449	,	_	_	_	_
4-56	450-453	and	_	_	_	_
4-57	454-463	apoptotic	object[28]	giv[28]	_	_
4-58	464-470	bodies	object[28]	giv[28]	_	_
4-59	471-472	,	object[28]	giv[28]	_	_
4-60	473-477	with	object[28]	giv[28]	_	_
4-61	478-479	a	object[28]|abstract[29]	giv[28]|new[29]	ana	5-24[0_29]
4-62	480-489	dimension	object[28]|abstract[29]	giv[28]|new[29]	_	_
4-63	490-497	similar	object[28]|abstract[29]	giv[28]|new[29]	_	_
4-64	498-500	to	_	_	_	_
4-65	501-510	platelets	object	new	_	_
4-66	511-512	,	_	_	_	_
4-67	513-520	derived	_	_	_	_
4-68	521-525	from	_	_	_	_
4-69	526-534	blebbing	event[31]	new[31]	_	_
4-70	535-537	of	event[31]	new[31]	_	_
4-71	538-543	dying	event[31]|object[32]	new[31]|new[32]	coref	7-27[57_32]
4-72	544-549	cells	event[31]|object[32]	new[31]|new[32]	_	_
4-73	550-551	.	_	_	_	_

#Text=Despite the distinct sizes and biogenesis , the absence of standardized isolation methods and the numerous similarities existing between these two subclasses make it particularly challenging to distinguish among them .
5-1	552-559	Despite	_	_	_	_
5-2	560-563	the	quantity[33]	new[33]	_	_
5-3	564-572	distinct	quantity[33]	new[33]	_	_
5-4	573-578	sizes	quantity[33]	new[33]	_	_
5-5	579-582	and	_	_	_	_
5-6	583-593	biogenesis	abstract	new	_	_
5-7	594-595	,	_	_	_	_
5-8	596-599	the	abstract[35]	new[35]	_	_
5-9	600-607	absence	abstract[35]	new[35]	_	_
5-10	608-610	of	abstract[35]	new[35]	_	_
5-11	611-623	standardized	abstract[35]|abstract[37]	new[35]|new[37]	_	_
5-12	624-633	isolation	abstract[35]|abstract|abstract[37]	new[35]|new|new[37]	_	_
5-13	634-641	methods	abstract[35]|abstract[37]	new[35]|new[37]	_	_
5-14	642-645	and	_	_	_	_
5-15	646-649	the	abstract[38]	new[38]	_	_
5-16	650-658	numerous	abstract[38]	new[38]	_	_
5-17	659-671	similarities	abstract[38]	new[38]	_	_
5-18	672-680	existing	_	_	_	_
5-19	681-688	between	_	_	_	_
5-20	689-694	these	abstract[39]	new[39]	ana	5-30[0_39]
5-21	695-698	two	abstract[39]	new[39]	_	_
5-22	699-709	subclasses	abstract[39]	new[39]	_	_
5-23	710-714	make	_	_	_	_
5-24	715-717	it	abstract	giv	_	_
5-25	718-730	particularly	_	_	_	_
5-26	731-742	challenging	_	_	_	_
5-27	743-745	to	_	_	_	_
5-28	746-757	distinguish	_	_	_	_
5-29	758-763	among	_	_	_	_
5-30	764-768	them	abstract	giv	_	_
5-31	769-770	.	_	_	_	_

#Text=In this review , we will use the generic term EVs to indicate both exosomes and microvesicles .
6-1	771-773	In	_	_	_	_
6-2	774-778	this	abstract[42]	new[42]	coref	22-7[192_42]
6-3	779-785	review	abstract[42]	new[42]	_	_
6-4	786-787	,	_	_	_	_
6-5	788-790	we	person	acc	ana	23-9
6-6	791-795	will	_	_	_	_
6-7	796-799	use	_	_	_	_
6-8	800-803	the	abstract[45]	giv[45]	coref	7-1[0_45]
6-9	804-811	generic	abstract[45]	giv[45]	_	_
6-10	812-816	term	abstract|abstract[45]	new|giv[45]	_	_
6-11	817-820	EVs	abstract[45]	giv[45]	_	_
6-12	821-823	to	_	_	_	_
6-13	824-832	indicate	_	_	_	_
6-14	833-837	both	object[46]|object[47]	giv[46]|giv[47]	_	_
6-15	838-846	exosomes	object[46]|object[47]	giv[46]|giv[47]	_	_
6-16	847-850	and	object[47]	giv[47]	_	_
6-17	851-864	microvesicles	object[47]|object	giv[47]|giv	_	_
6-18	865-866	.	_	_	_	_

#Text=EVs have been shown to carry functionally active biological materials including proteins , mRNAs and miRNAs , which makes them capable of transmitting signals to target cells in the surrounding environment as well as to distant organs , via blood and lymphatic vessels .
7-1	867-870	EVs	abstract	giv	coref	8-13
7-2	871-875	have	_	_	_	_
7-3	876-880	been	_	_	_	_
7-4	881-886	shown	_	_	_	_
7-5	887-889	to	_	_	_	_
7-6	890-895	carry	_	_	_	_
7-7	896-908	functionally	substance[50]	new[50]	_	_
7-8	909-915	active	substance[50]	new[50]	_	_
7-9	916-926	biological	substance[50]	new[50]	_	_
7-10	927-936	materials	substance[50]	new[50]	_	_
7-11	937-946	including	substance[50]	new[50]	_	_
7-12	947-955	proteins	substance[50]|substance|abstract[52]	new[50]|new|new[52]	ana|coref|ana|coref	7-20[0_52]|14-16[122_0]|7-20[0_52]|14-16[122_0]
7-13	956-957	,	substance[50]|abstract[52]	new[50]|new[52]	_	_
7-14	958-963	mRNAs	substance[50]|abstract[52]|object	new[50]|new[52]|new	_	_
7-15	964-967	and	substance[50]|abstract[52]	new[50]|new[52]	_	_
7-16	968-974	miRNAs	substance[50]|abstract[52]|person	new[50]|new[52]|new	_	_
7-17	975-976	,	_	_	_	_
7-18	977-982	which	_	_	_	_
7-19	983-988	makes	_	_	_	_
7-20	989-993	them	abstract	giv	_	_
7-21	994-1001	capable	_	_	_	_
7-22	1002-1004	of	_	_	_	_
7-23	1005-1017	transmitting	_	_	_	_
7-24	1018-1025	signals	abstract	new	_	_
7-25	1026-1028	to	_	_	_	_
7-26	1029-1035	target	abstract	new	coref|none	22-36[200_0]|7-26[0_200]
7-27	1036-1041	cells	object[57]	giv[57]	coref	10-11[81_57]
7-28	1042-1044	in	object[57]	giv[57]	_	_
7-29	1045-1048	the	object[57]|place[58]	giv[57]|new[58]	_	_
7-30	1049-1060	surrounding	object[57]|place[58]	giv[57]|new[58]	_	_
7-31	1061-1072	environment	object[57]|place[58]	giv[57]|new[58]	_	_
7-32	1073-1075	as	object[57]	giv[57]	_	_
7-33	1076-1080	well	object[57]	giv[57]	_	_
7-34	1081-1083	as	object[57]	giv[57]	_	_
7-35	1084-1086	to	object[57]	giv[57]	_	_
7-36	1087-1094	distant	object[57]|object[59]	giv[57]|new[59]	coref	20-24[182_59]
7-37	1095-1101	organs	object[57]|object[59]	giv[57]|new[59]	_	_
7-38	1102-1103	,	object[57]|object[59]	giv[57]|new[59]	_	_
7-39	1104-1107	via	object[57]|object[59]	giv[57]|new[59]	_	_
7-40	1108-1113	blood	object[57]|object[59]|substance|object[61]	giv[57]|new[59]|new|new[61]	coref|coref|coref|coref	10-16|12-21[112_61]|10-16|12-21[112_61]
7-41	1114-1117	and	object[57]|object[59]|object[61]	giv[57]|new[59]|new[61]	_	_
7-42	1118-1127	lymphatic	object[57]|object[59]|object[61]	giv[57]|new[59]|new[61]	_	_
7-43	1128-1135	vessels	object[57]|object[59]|object[61]	giv[57]|new[59]|new[61]	_	_
7-44	1136-1137	.	_	_	_	_

#Text=The scientific community has recently turned its interest toward the evaluation of EVs as drug delivery vehicles .
8-1	1138-1141	The	organization[62]	new[62]	ana	8-7[0_62]
8-2	1142-1152	scientific	organization[62]	new[62]	_	_
8-3	1153-1162	community	organization[62]	new[62]	_	_
8-4	1163-1166	has	_	_	_	_
8-5	1167-1175	recently	_	_	_	_
8-6	1176-1182	turned	_	_	_	_
8-7	1183-1186	its	organization|abstract[64]	giv|new[64]	coref|coref|coref|coref	21-11[187_0]|21-10[188_64]|21-11[187_0]|21-10[188_64]
8-8	1187-1195	interest	abstract[64]	new[64]	_	_
8-9	1196-1202	toward	_	_	_	_
8-10	1203-1206	the	abstract[65]	new[65]	_	_
8-11	1207-1217	evaluation	abstract[65]	new[65]	_	_
8-12	1218-1220	of	abstract[65]	new[65]	_	_
8-13	1221-1224	EVs	abstract[65]|abstract	new[65]|giv	coref	9-5
8-14	1225-1227	as	abstract[65]	new[65]	_	_
8-15	1228-1232	drug	abstract[65]|substance	new[65]|new	coref	9-11
8-16	1233-1241	delivery	abstract[65]|abstract	new[65]|new	coref	9-12
8-17	1242-1250	vehicles	abstract[65]	new[65]	_	_
8-18	1251-1252	.	_	_	_	_

#Text=In this context , EVs offer significant advantages over current drug delivery systems , such as liposomes and polymeric nanoparticles .
9-1	1253-1255	In	_	_	_	_
9-2	1256-1260	this	abstract[69]	new[69]	_	_
9-3	1261-1268	context	abstract[69]	new[69]	_	_
9-4	1269-1270	,	_	_	_	_
9-5	1271-1274	EVs	abstract	giv	coref	10-2
9-6	1275-1280	offer	_	_	_	_
9-7	1281-1292	significant	abstract[71]	new[71]	_	_
9-8	1293-1303	advantages	abstract[71]	new[71]	_	_
9-9	1304-1308	over	abstract[71]	new[71]	_	_
9-10	1309-1316	current	abstract[71]|abstract[74]	new[71]|new[74]	coref	15-6[135_74]
9-11	1317-1321	drug	abstract[71]|substance|abstract[74]	new[71]|giv|new[74]	coref	11-26[93_0]
9-12	1322-1330	delivery	abstract[71]|abstract|abstract[74]	new[71]|giv|new[74]	coref	15-8
9-13	1331-1338	systems	abstract[71]|abstract[74]	new[71]|new[74]	_	_
9-14	1339-1340	,	abstract[71]|abstract[74]	new[71]|new[74]	_	_
9-15	1341-1345	such	abstract[71]|abstract[74]	new[71]|new[74]	_	_
9-16	1346-1348	as	abstract[71]|abstract[74]	new[71]|new[74]	_	_
9-17	1349-1358	liposomes	abstract[71]|abstract[74]|object	new[71]|new[74]|new	coref	15-2[136_0]
9-18	1359-1362	and	abstract[71]|abstract[74]	new[71]|new[74]	_	_
9-19	1363-1372	polymeric	abstract[71]|abstract[74]|object[76]	new[71]|new[74]|new[76]	coref	14-42[131_76]
9-20	1373-1386	nanoparticles	abstract[71]|abstract[74]|object[76]	new[71]|new[74]|new[76]	_	_
9-21	1387-1388	.	_	_	_	_

#Text=Since EVs can be obtained with an autologous procedure from the patient ’s cells or blood , they do not solicit the immune system as usual synthetic formulations do .
10-1	1389-1394	Since	_	_	_	_
10-2	1395-1398	EVs	abstract	giv	coref	11-9
10-3	1399-1402	can	_	_	_	_
10-4	1403-1405	be	_	_	_	_
10-5	1406-1414	obtained	_	_	_	_
10-6	1415-1419	with	_	_	_	_
10-7	1420-1422	an	abstract[79]	new[79]	_	_
10-8	1423-1433	autologous	person|abstract[79]	new|new[79]	_	_
10-9	1434-1443	procedure	abstract[79]	new[79]	_	_
10-10	1444-1448	from	abstract[79]	new[79]	_	_
10-11	1449-1452	the	abstract[79]|object[81]	new[79]|giv[81]	ana	10-18[0_81]
10-12	1453-1460	patient	abstract[79]|person[80]|object[81]	new[79]|new[80]|giv[81]	_	_
10-13	1461-1463	’s	abstract[79]|person[80]|object[81]	new[79]|new[80]|giv[81]	_	_
10-14	1464-1469	cells	abstract[79]|object[81]	new[79]|giv[81]	_	_
10-15	1470-1472	or	abstract[79]|object[81]	new[79]|giv[81]	_	_
10-16	1473-1478	blood	abstract[79]|object[81]|substance	new[79]|giv[81]|giv	_	_
10-17	1479-1480	,	_	_	_	_
10-18	1481-1485	they	object	giv	_	_
10-19	1486-1488	do	_	_	_	_
10-20	1489-1492	not	_	_	_	_
10-21	1493-1500	solicit	_	_	_	_
10-22	1501-1504	the	place[84]	new[84]	coref	11-59[105_84]
10-23	1505-1511	immune	place[84]	new[84]	_	_
10-24	1512-1518	system	place[84]	new[84]	_	_
10-25	1519-1521	as	_	_	_	_
10-26	1522-1527	usual	object[85]	new[85]	ana	11-5[0_85]
10-27	1528-1537	synthetic	object[85]	new[85]	_	_
10-28	1538-1550	formulations	object[85]	new[85]	_	_
10-29	1551-1553	do	_	_	_	_
10-30	1554-1555	.	_	_	_	_

#Text=In addition , given their phospholipid bilayer , EVs can directly fuse with the targeted plasma membrane , thus allowing a more efficient internalization of the encapsulated drug . Their hydrophilic shell , together with the presence of anti-phagocytosis surface markers ( i. e. , CD47 ) , enables them to evade phagocytosis by monocytes and macrophages of the reticulo-endothelial system , hence weakening their clearance .
11-1	1556-1558	In	_	_	_	_
11-2	1559-1567	addition	_	_	_	_
11-3	1568-1569	,	_	_	_	_
11-4	1570-1575	given	_	_	_	_
11-5	1576-1581	their	object|object[88]	giv|new[88]	ana|ana	11-30|11-30
11-6	1582-1594	phospholipid	person|object[88]	new|new[88]	_	_
11-7	1595-1602	bilayer	object[88]	new[88]	_	_
11-8	1603-1604	,	_	_	_	_
11-9	1605-1608	EVs	abstract	giv	coref	17-17
11-10	1609-1612	can	_	_	_	_
11-11	1613-1621	directly	_	_	_	_
11-12	1622-1626	fuse	_	_	_	_
11-13	1627-1631	with	_	_	_	_
11-14	1632-1635	the	object[91]	giv[91]	coref	14-8[0_91]
11-15	1636-1644	targeted	object[91]	giv[91]	_	_
11-16	1645-1651	plasma	abstract|object[91]	new|giv[91]	_	_
11-17	1652-1660	membrane	object[91]	giv[91]	_	_
11-18	1661-1662	,	_	_	_	_
11-19	1663-1667	thus	_	_	_	_
11-20	1668-1676	allowing	_	_	_	_
11-21	1677-1678	a	abstract[92]	new[92]	_	_
11-22	1679-1683	more	abstract[92]	new[92]	_	_
11-23	1684-1693	efficient	abstract[92]	new[92]	_	_
11-24	1694-1709	internalization	abstract[92]	new[92]	_	_
11-25	1710-1712	of	abstract[92]	new[92]	_	_
11-26	1713-1716	the	abstract[92]|substance[93]	new[92]|giv[93]	coref	15-7[0_93]
11-27	1717-1729	encapsulated	abstract[92]|substance[93]	new[92]|giv[93]	_	_
11-28	1730-1734	drug	abstract[92]|substance[93]	new[92]|giv[93]	_	_
11-29	1735-1736	.	_	_	_	_
11-30	1737-1742	Their	object|object[95]	giv|new[95]	ana|ana	11-50|11-50
11-31	1743-1754	hydrophilic	object[95]	new[95]	_	_
11-32	1755-1760	shell	object[95]	new[95]	_	_
11-33	1761-1762	,	_	_	_	_
11-34	1763-1771	together	abstract[96]	new[96]	_	_
11-35	1772-1776	with	abstract[96]	new[96]	_	_
11-36	1777-1780	the	abstract[96]	new[96]	_	_
11-37	1781-1789	presence	abstract[96]	new[96]	_	_
11-38	1790-1792	of	abstract[96]	new[96]	_	_
11-39	1793-1810	anti-phagocytosis	abstract[96]|place|abstract[99]	new[96]|new|new[99]	_	_
11-40	1811-1818	surface	abstract[96]|place|abstract[99]	new[96]|new|new[99]	_	_
11-41	1819-1826	markers	abstract[96]|abstract[99]	new[96]|new[99]	_	_
11-42	1827-1828	(	_	_	_	_
11-43	1829-1831	i.	_	_	_	_
11-44	1832-1834	e.	_	_	_	_
11-45	1835-1836	,	_	_	_	_
11-46	1837-1841	CD47	object	new	_	_
11-47	1842-1843	)	_	_	_	_
11-48	1844-1845	,	_	_	_	_
11-49	1846-1853	enables	_	_	_	_
11-50	1854-1858	them	object	giv	ana	11-65
11-51	1859-1861	to	_	_	_	_
11-52	1862-1867	evade	_	_	_	_
11-53	1868-1880	phagocytosis	abstract	new	_	_
11-54	1881-1883	by	_	_	_	_
11-55	1884-1893	monocytes	object	new	_	_
11-56	1894-1897	and	_	_	_	_
11-57	1898-1909	macrophages	object[104]	new[104]	_	_
11-58	1910-1912	of	object[104]	new[104]	_	_
11-59	1913-1916	the	object[104]|place[105]	new[104]|giv[105]	_	_
11-60	1917-1937	reticulo-endothelial	object[104]|place[105]	new[104]|giv[105]	_	_
11-61	1938-1944	system	object[104]|place[105]	new[104]|giv[105]	_	_
11-62	1945-1946	,	_	_	_	_
11-63	1947-1952	hence	_	_	_	_
11-64	1953-1962	weakening	_	_	_	_
11-65	1963-1968	their	object|abstract[107]	giv|new[107]	ana|ana	12-7|12-7
11-66	1969-1978	clearance	abstract[107]	new[107]	_	_
11-67	1979-1980	.	_	_	_	_

#Text=Moreover , the limited size allows them to efficiently extravasate through the inter-endothelial junctions and fenestrations of both existing and neo-synthesized vessels .
12-1	1981-1989	Moreover	_	_	_	_
12-2	1990-1991	,	_	_	_	_
12-3	1992-1995	the	quantity[108]	new[108]	_	_
12-4	1996-2003	limited	quantity[108]	new[108]	_	_
12-5	2004-2008	size	quantity[108]	new[108]	_	_
12-6	2009-2015	allows	_	_	_	_
12-7	2016-2020	them	object	giv	coref	16-17[144_0]
12-8	2021-2023	to	_	_	_	_
12-9	2024-2035	efficiently	_	_	_	_
12-10	2036-2047	extravasate	_	_	_	_
12-11	2048-2055	through	_	_	_	_
12-12	2056-2059	the	place[110]	new[110]	_	_
12-13	2060-2077	inter-endothelial	place[110]	new[110]	_	_
12-14	2078-2087	junctions	place[110]	new[110]	_	_
12-15	2088-2091	and	_	_	_	_
12-16	2092-2105	fenestrations	abstract[111]	new[111]	_	_
12-17	2106-2108	of	abstract[111]	new[111]	_	_
12-18	2109-2113	both	abstract[111]	new[111]	_	_
12-19	2114-2122	existing	abstract[111]	new[111]	_	_
12-20	2123-2126	and	abstract[111]	new[111]	_	_
12-21	2127-2142	neo-synthesized	abstract[111]|object[112]	new[111]|giv[112]	_	_
12-22	2143-2150	vessels	abstract[111]|object[112]	new[111]|giv[112]	_	_
12-23	2151-2152	.	_	_	_	_

#Text=Thanks to these peculiar characteristics , they can spread and accumulate in the parenchyma of solid tumors .
13-1	2153-2159	Thanks	_	_	_	_
13-2	2160-2162	to	_	_	_	_
13-3	2163-2168	these	abstract[113]	new[113]	ana	13-7[0_113]
13-4	2169-2177	peculiar	abstract[113]	new[113]	_	_
13-5	2178-2193	characteristics	abstract[113]	new[113]	_	_
13-6	2194-2195	,	_	_	_	_
13-7	2196-2200	they	abstract	giv	_	_
13-8	2201-2204	can	_	_	_	_
13-9	2205-2211	spread	_	_	_	_
13-10	2212-2215	and	_	_	_	_
13-11	2216-2226	accumulate	_	_	_	_
13-12	2227-2229	in	_	_	_	_
13-13	2230-2233	the	place[115]	new[115]	_	_
13-14	2234-2244	parenchyma	place[115]	new[115]	_	_
13-15	2245-2247	of	place[115]	new[115]	_	_
13-16	2248-2253	solid	place[115]|object[116]	new[115]|new[116]	_	_
13-17	2254-2260	tumors	place[115]|object[116]	new[115]|new[116]	_	_
13-18	2261-2262	.	_	_	_	_

#Text=EV biological properties derive from their sophisticated membrane structure , characterized by the presence of several proteins for active targeting , adhesion , cell fusion , and intracellular release of their content ; this functional complexity is not easily reproduced by de novo synthesized nanoparticles .
14-1	2263-2265	EV	abstract[117]	new[117]	ana	14-6[0_117]
14-2	2266-2276	biological	abstract[117]	new[117]	_	_
14-3	2277-2287	properties	abstract[117]	new[117]	_	_
14-4	2288-2294	derive	_	_	_	_
14-5	2295-2299	from	_	_	_	_
14-6	2300-2305	their	abstract|abstract[120]	giv|new[120]	ana|ana	14-31|14-31
14-7	2306-2319	sophisticated	abstract[120]	new[120]	_	_
14-8	2320-2328	membrane	object|abstract[120]	giv|new[120]	_	_
14-9	2329-2338	structure	abstract[120]	new[120]	_	_
14-10	2339-2340	,	_	_	_	_
14-11	2341-2354	characterized	_	_	_	_
14-12	2355-2357	by	_	_	_	_
14-13	2358-2361	the	abstract[121]	new[121]	_	_
14-14	2362-2370	presence	abstract[121]	new[121]	_	_
14-15	2371-2373	of	abstract[121]	new[121]	_	_
14-16	2374-2381	several	abstract[121]|substance[122]	new[121]|giv[122]	_	_
14-17	2382-2390	proteins	abstract[121]|substance[122]	new[121]|giv[122]	_	_
14-18	2391-2394	for	abstract[121]|substance[122]	new[121]|giv[122]	_	_
14-19	2395-2401	active	abstract[121]|substance[122]|event[123]	new[121]|giv[122]|new[123]	_	_
14-20	2402-2411	targeting	abstract[121]|substance[122]|event[123]	new[121]|giv[122]|new[123]	_	_
14-21	2412-2413	,	abstract[121]|substance[122]	new[121]|giv[122]	_	_
14-22	2414-2422	adhesion	abstract[121]|substance[122]|abstract	new[121]|giv[122]|new	_	_
14-23	2423-2424	,	abstract[121]|substance[122]	new[121]|giv[122]	_	_
14-24	2425-2429	cell	abstract[121]|substance[122]|place|event[126]	new[121]|giv[122]|giv|new[126]	_	_
14-25	2430-2436	fusion	abstract[121]|substance[122]|event[126]	new[121]|giv[122]|new[126]	_	_
14-26	2437-2438	,	abstract[121]|substance[122]	new[121]|giv[122]	_	_
14-27	2439-2442	and	abstract[121]|substance[122]	new[121]|giv[122]	_	_
14-28	2443-2456	intracellular	abstract[121]|substance[122]|event[127]	new[121]|giv[122]|new[127]	_	_
14-29	2457-2464	release	abstract[121]|substance[122]|event[127]	new[121]|giv[122]|new[127]	_	_
14-30	2465-2467	of	abstract[121]|substance[122]|event[127]	new[121]|giv[122]|new[127]	_	_
14-31	2468-2473	their	abstract[121]|substance[122]|event[127]|abstract|abstract[129]	new[121]|giv[122]|new[127]|giv|new[129]	_	_
14-32	2474-2481	content	abstract[121]|substance[122]|event[127]|abstract[129]	new[121]|giv[122]|new[127]|new[129]	_	_
14-33	2482-2483	;	_	_	_	_
14-34	2484-2488	this	abstract[130]	new[130]	_	_
14-35	2489-2499	functional	abstract[130]	new[130]	_	_
14-36	2500-2510	complexity	abstract[130]	new[130]	_	_
14-37	2511-2513	is	_	_	_	_
14-38	2514-2517	not	_	_	_	_
14-39	2518-2524	easily	_	_	_	_
14-40	2525-2535	reproduced	_	_	_	_
14-41	2536-2538	by	_	_	_	_
14-42	2539-2541	de	object[131]	giv[131]	_	_
14-43	2542-2546	novo	object[131]	giv[131]	_	_
14-44	2547-2558	synthesized	object[131]	giv[131]	_	_
14-45	2559-2572	nanoparticles	object[131]	giv[131]	_	_
14-46	2573-2574	.	_	_	_	_

#Text=Among the several types of nano-based drug delivery systems , liposomes are probably the most used , due to their non-toxicity and capacity to accommodate high amounts of compounds .
15-1	2575-2580	Among	_	_	_	_
15-2	2581-2584	the	abstract[132]|object[136]	new[132]|giv[136]	ana|ana	15-20[0_136]|15-20[0_136]
15-3	2585-2592	several	abstract[132]|object[136]	new[132]|giv[136]	_	_
15-4	2593-2598	types	abstract[132]|object[136]	new[132]|giv[136]	_	_
15-5	2599-2601	of	abstract[132]|object[136]	new[132]|giv[136]	_	_
15-6	2602-2612	nano-based	abstract[132]|abstract[135]|object[136]	new[132]|giv[135]|giv[136]	_	_
15-7	2613-2617	drug	abstract[132]|substance|abstract[135]|object[136]	new[132]|giv|giv[135]|giv[136]	coref	17-21
15-8	2618-2626	delivery	abstract[132]|abstract|abstract[135]|object[136]	new[132]|giv|giv[135]|giv[136]	coref	17-21[154_0]
15-9	2627-2634	systems	abstract[132]|abstract[135]|object[136]	new[132]|giv[135]|giv[136]	_	_
15-10	2635-2636	,	object[136]	giv[136]	_	_
15-11	2637-2646	liposomes	object[136]	giv[136]	_	_
15-12	2647-2650	are	_	_	_	_
15-13	2651-2659	probably	_	_	_	_
15-14	2660-2663	the	_	_	_	_
15-15	2664-2668	most	_	_	_	_
15-16	2669-2673	used	_	_	_	_
15-17	2674-2675	,	_	_	_	_
15-18	2676-2679	due	_	_	_	_
15-19	2680-2682	to	_	_	_	_
15-20	2683-2688	their	object	giv	_	_
15-21	2689-2701	non-toxicity	_	_	_	_
15-22	2702-2705	and	_	_	_	_
15-23	2706-2714	capacity	abstract	new	_	_
15-24	2715-2717	to	_	_	_	_
15-25	2718-2729	accommodate	_	_	_	_
15-26	2730-2734	high	object[139]	new[139]	_	_
15-27	2735-2742	amounts	object[139]	new[139]	_	_
15-28	2743-2745	of	object[139]	new[139]	_	_
15-29	2746-2755	compounds	object[139]|substance	new[139]|new	_	_
15-30	2756-2757	.	_	_	_	_

#Text=However , a still inadequate in vivo targeting efficiency together with a potential immunogenicity associated to liposomal formulations has limited their broad applicability in therapeutics .
16-1	2758-2765	However	_	_	_	_
16-2	2766-2767	,	_	_	_	_
16-3	2768-2769	a	_	_	_	_
16-4	2770-2775	still	_	_	_	_
16-5	2776-2786	inadequate	_	_	_	_
16-6	2787-2789	in	_	_	_	_
16-7	2790-2794	vivo	_	_	_	_
16-8	2795-2804	targeting	_	_	_	_
16-9	2805-2815	efficiency	abstract[141]	new[141]	_	_
16-10	2816-2824	together	abstract[141]	new[141]	_	_
16-11	2825-2829	with	abstract[141]	new[141]	_	_
16-12	2830-2831	a	abstract[141]|abstract[142]	new[141]|new[142]	_	_
16-13	2832-2841	potential	abstract[141]|abstract[142]	new[141]|new[142]	_	_
16-14	2842-2856	immunogenicity	abstract[141]|abstract[142]	new[141]|new[142]	_	_
16-15	2857-2867	associated	_	_	_	_
16-16	2868-2870	to	_	_	_	_
16-17	2871-2880	liposomal	animal|object[144]	new|giv[144]	ana|ana	16-21[0_144]|16-21[0_144]
16-18	2881-2893	formulations	object[144]	giv[144]	_	_
16-19	2894-2897	has	_	_	_	_
16-20	2898-2905	limited	_	_	_	_
16-21	2906-2911	their	object|abstract[146]	giv|new[146]	coref|coref	19-14[169_0]|19-14[169_0]
16-22	2912-2917	broad	abstract[146]	new[146]	_	_
16-23	2918-2931	applicability	abstract[146]	new[146]	_	_
16-24	2932-2934	in	abstract[146]	new[146]	_	_
16-25	2935-2947	therapeutics	abstract[146]|abstract	new[146]|new	_	_
16-26	2948-2949	.	_	_	_	_

#Text=Therefore , the greater specificity combined with the consequent limited induction of systemic side effects make EVs ideal vehicles for drug delivery .
17-1	2950-2959	Therefore	_	_	_	_
17-2	2960-2961	,	_	_	_	_
17-3	2962-2965	the	abstract[148]	new[148]	_	_
17-4	2966-2973	greater	abstract[148]	new[148]	_	_
17-5	2974-2985	specificity	abstract[148]	new[148]	_	_
17-6	2986-2994	combined	_	_	_	_
17-7	2995-2999	with	_	_	_	_
17-8	3000-3003	the	abstract[149]	new[149]	_	_
17-9	3004-3014	consequent	abstract[149]	new[149]	_	_
17-10	3015-3022	limited	abstract[149]	new[149]	_	_
17-11	3023-3032	induction	abstract[149]	new[149]	_	_
17-12	3033-3035	of	abstract[149]	new[149]	_	_
17-13	3036-3044	systemic	abstract[149]|abstract[150]	new[149]|new[150]	coref	20-29[183_150]
17-14	3045-3049	side	abstract[149]|abstract[150]	new[149]|new[150]	_	_
17-15	3050-3057	effects	abstract[149]|abstract[150]	new[149]|new[150]	_	_
17-16	3058-3062	make	_	_	_	_
17-17	3063-3066	EVs	abstract|object[152]	giv|new[152]	coref|coref	18-18[161_0]|18-18[161_0]
17-18	3067-3072	ideal	object[152]	new[152]	_	_
17-19	3073-3081	vehicles	object[152]	new[152]	_	_
17-20	3082-3085	for	object[152]	new[152]	_	_
17-21	3086-3090	drug	object[152]|substance|abstract[154]	new[152]|giv|giv[154]	ana|coref|ana|coref	18-7[0_154]|20-21|18-7[0_154]|20-21
17-22	3091-3099	delivery	object[152]|abstract[154]	new[152]|giv[154]	_	_
17-23	3100-3101	.	_	_	_	_

#Text=Although this research field is in its infancy , in the last decade , the use of bio-engineered EVs for the delivery of cytotoxic molecules in preclinical models has produced encouraging results .
18-1	3102-3110	Although	_	_	_	_
18-2	3111-3115	this	abstract[156]	new[156]	coref	21-17[190_156]
18-3	3116-3124	research	abstract|abstract[156]	new|new[156]	coref	21-19
18-4	3125-3130	field	abstract[156]	new[156]	_	_
18-5	3131-3133	is	_	_	_	_
18-6	3134-3136	in	_	_	_	_
18-7	3137-3140	its	abstract|time[158]	giv|new[158]	coref|coref	18-21[162_0]|18-21[162_0]
18-8	3141-3148	infancy	time[158]	new[158]	_	_
18-9	3149-3150	,	time[158]	new[158]	_	_
18-10	3151-3153	in	time[158]	new[158]	_	_
18-11	3154-3157	the	time[158]|time[159]	new[158]|new[159]	_	_
18-12	3158-3162	last	time[158]|time[159]	new[158]|new[159]	_	_
18-13	3163-3169	decade	time[158]|time[159]	new[158]|new[159]	_	_
18-14	3170-3171	,	_	_	_	_
18-15	3172-3175	the	abstract[160]	new[160]	_	_
18-16	3176-3179	use	abstract[160]	new[160]	_	_
18-17	3180-3182	of	abstract[160]	new[160]	_	_
18-18	3183-3197	bio-engineered	abstract[160]|abstract[161]	new[160]|giv[161]	coref	22-19[0_161]
18-19	3198-3201	EVs	abstract[160]|abstract[161]	new[160]|giv[161]	_	_
18-20	3202-3205	for	abstract[160]	new[160]	_	_
18-21	3206-3209	the	abstract[160]|abstract[162]	new[160]|giv[162]	coref	22-22[0_162]
18-22	3210-3218	delivery	abstract[160]|abstract[162]	new[160]|giv[162]	_	_
18-23	3219-3221	of	abstract[160]|abstract[162]	new[160]|giv[162]	_	_
18-24	3222-3231	cytotoxic	abstract[160]|abstract[162]|object[163]	new[160]|giv[162]|new[163]	coref	22-31[199_163]
18-25	3232-3241	molecules	abstract[160]|abstract[162]|object[163]	new[160]|giv[162]|new[163]	_	_
18-26	3242-3244	in	abstract[160]|abstract[162]|object[163]	new[160]|giv[162]|new[163]	_	_
18-27	3245-3256	preclinical	abstract[160]|abstract[162]|object[163]|abstract[164]	new[160]|giv[162]|new[163]|new[164]	_	_
18-28	3257-3263	models	abstract[160]|abstract[162]|object[163]|abstract[164]	new[160]|giv[162]|new[163]|new[164]	_	_
18-29	3264-3267	has	_	_	_	_
18-30	3268-3276	produced	_	_	_	_
18-31	3277-3288	encouraging	_	_	_	_
18-32	3289-3296	results	abstract	new	_	_
18-33	3297-3298	.	_	_	_	_

#Text=These experimental evidences , in addition to preliminary clinical data , indicate that EV formulations may not only enhance the safety and biodistribution of commonly used drugs , but also increase their efficacy .
19-1	3299-3304	These	abstract[166]	new[166]	_	_
19-2	3305-3317	experimental	abstract[166]	new[166]	_	_
19-3	3318-3327	evidences	abstract[166]	new[166]	_	_
19-4	3328-3329	,	abstract[166]	new[166]	_	_
19-5	3330-3332	in	abstract[166]	new[166]	_	_
19-6	3333-3341	addition	abstract[166]	new[166]	_	_
19-7	3342-3344	to	abstract[166]	new[166]	_	_
19-8	3345-3356	preliminary	abstract[166]|abstract[167]	new[166]|new[167]	_	_
19-9	3357-3365	clinical	abstract[166]|abstract[167]	new[166]|new[167]	_	_
19-10	3366-3370	data	abstract[166]|abstract[167]	new[166]|new[167]	_	_
19-11	3371-3372	,	_	_	_	_
19-12	3373-3381	indicate	_	_	_	_
19-13	3382-3386	that	_	_	_	_
19-14	3387-3389	EV	abstract|object[169]	new|giv[169]	_	_
19-15	3390-3402	formulations	object[169]	giv[169]	_	_
19-16	3403-3406	may	_	_	_	_
19-17	3407-3410	not	_	_	_	_
19-18	3411-3415	only	_	_	_	_
19-19	3416-3423	enhance	_	_	_	_
19-20	3424-3427	the	abstract[170]	new[170]	_	_
19-21	3428-3434	safety	abstract[170]	new[170]	_	_
19-22	3435-3438	and	_	_	_	_
19-23	3439-3454	biodistribution	substance[171]	new[171]	_	_
19-24	3455-3457	of	substance[171]	new[171]	_	_
19-25	3458-3466	commonly	substance[171]|substance[172]	new[171]|new[172]	ana	19-32[0_172]
19-26	3467-3471	used	substance[171]|substance[172]	new[171]|new[172]	_	_
19-27	3472-3477	drugs	substance[171]|substance[172]	new[171]|new[172]	_	_
19-28	3478-3479	,	_	_	_	_
19-29	3480-3483	but	_	_	_	_
19-30	3484-3488	also	_	_	_	_
19-31	3489-3497	increase	_	_	_	_
19-32	3498-3503	their	substance|abstract[174]	giv|new[174]	ana|coref|ana|coref	20-4[0_174]|20-12[178_0]|20-4[0_174]|20-12[178_0]
19-33	3504-3512	efficacy	abstract[174]	new[174]	_	_
19-34	3513-3514	.	_	_	_	_

#Text=For example , it has been demonstrated that the administration of EV-encapsulating chemotherapy drugs leads to a significant reduction of drug accumulation in off-target organs , thus preventing important side effects during standard clinical protocols .
20-1	3515-3518	For	_	_	_	_
20-2	3519-3526	example	_	_	_	_
20-3	3527-3528	,	_	_	_	_
20-4	3529-3531	it	abstract	giv	_	_
20-5	3532-3535	has	_	_	_	_
20-6	3536-3540	been	_	_	_	_
20-7	3541-3553	demonstrated	_	_	_	_
20-8	3554-3558	that	_	_	_	_
20-9	3559-3562	the	event[176]	new[176]	_	_
20-10	3563-3577	administration	event[176]	new[176]	_	_
20-11	3578-3580	of	event[176]	new[176]	_	_
20-12	3581-3597	EV-encapsulating	event[176]|substance[178]	new[176]|giv[178]	_	_
20-13	3598-3610	chemotherapy	event[176]|abstract|substance[178]	new[176]|new|giv[178]	_	_
20-14	3611-3616	drugs	event[176]|substance[178]	new[176]|giv[178]	_	_
20-15	3617-3622	leads	_	_	_	_
20-16	3623-3625	to	_	_	_	_
20-17	3626-3627	a	abstract[179]	new[179]	_	_
20-18	3628-3639	significant	abstract[179]	new[179]	_	_
20-19	3640-3649	reduction	abstract[179]	new[179]	_	_
20-20	3650-3652	of	abstract[179]	new[179]	_	_
20-21	3653-3657	drug	abstract[179]|substance|abstract[181]	new[179]|giv|new[181]	coref|coref	22-21|22-21
20-22	3658-3670	accumulation	abstract[179]|abstract[181]	new[179]|new[181]	_	_
20-23	3671-3673	in	abstract[179]|abstract[181]	new[179]|new[181]	_	_
20-24	3674-3684	off-target	abstract[179]|abstract[181]|object[182]	new[179]|new[181]|giv[182]	_	_
20-25	3685-3691	organs	abstract[179]|abstract[181]|object[182]	new[179]|new[181]|giv[182]	_	_
20-26	3692-3693	,	_	_	_	_
20-27	3694-3698	thus	_	_	_	_
20-28	3699-3709	preventing	_	_	_	_
20-29	3710-3719	important	abstract[183]	giv[183]	_	_
20-30	3720-3724	side	abstract[183]	giv[183]	_	_
20-31	3725-3732	effects	abstract[183]	giv[183]	_	_
20-32	3733-3739	during	_	_	_	_
20-33	3740-3748	standard	event[184]	new[184]	_	_
20-34	3749-3757	clinical	event[184]	new[184]	_	_
20-35	3758-3767	protocols	event[184]	new[184]	_	_
20-36	3768-3769	.	_	_	_	_

#Text=An astonishing number of newly published papers perfectly depict the scientific community ’s authentic interest in this flourishing research field .
21-1	3770-3772	An	abstract[185]	new[185]	_	_
21-2	3773-3784	astonishing	abstract[185]	new[185]	_	_
21-3	3785-3791	number	abstract[185]	new[185]	_	_
21-4	3792-3794	of	abstract[185]	new[185]	_	_
21-5	3795-3800	newly	abstract[185]|object[186]	new[185]|new[186]	_	_
21-6	3801-3810	published	abstract[185]|object[186]	new[185]|new[186]	_	_
21-7	3811-3817	papers	abstract[185]|object[186]	new[185]|new[186]	_	_
21-8	3818-3827	perfectly	_	_	_	_
21-9	3828-3834	depict	_	_	_	_
21-10	3835-3838	the	abstract[188]	giv[188]	_	_
21-11	3839-3849	scientific	organization[187]|abstract[188]	giv[187]|giv[188]	_	_
21-12	3850-3859	community	organization[187]|abstract[188]	giv[187]|giv[188]	_	_
21-13	3860-3862	’s	organization[187]|abstract[188]	giv[187]|giv[188]	_	_
21-14	3863-3872	authentic	abstract[188]	giv[188]	_	_
21-15	3873-3881	interest	abstract[188]	giv[188]	_	_
21-16	3882-3884	in	abstract[188]	giv[188]	_	_
21-17	3885-3889	this	abstract[188]|abstract[190]	giv[188]|giv[190]	_	_
21-18	3890-3901	flourishing	abstract[188]|abstract[190]	giv[188]|giv[190]	_	_
21-19	3902-3910	research	abstract[188]|abstract|abstract[190]	giv[188]|giv|giv[190]	_	_
21-20	3911-3916	field	abstract[188]|abstract[190]	giv[188]|giv[190]	_	_
21-21	3917-3918	.	_	_	_	_

#Text=Nevertheless , the first aim of this review is to disclose an overview of the latest applications of EVs as drug delivery vehicles , focusing on the sources employed , the molecules selected , and the final intended targets .
22-1	3919-3931	Nevertheless	_	_	_	_
22-2	3932-3933	,	_	_	_	_
22-3	3934-3937	the	abstract[191]	new[191]	_	_
22-4	3938-3943	first	abstract[191]	new[191]	_	_
22-5	3944-3947	aim	abstract[191]	new[191]	_	_
22-6	3948-3950	of	abstract[191]	new[191]	_	_
22-7	3951-3955	this	abstract[191]|abstract[192]	new[191]|giv[192]	coref	23-6[201_192]
22-8	3956-3962	review	abstract[191]|abstract[192]	new[191]|giv[192]	_	_
22-9	3963-3965	is	_	_	_	_
22-10	3966-3968	to	_	_	_	_
22-11	3969-3977	disclose	_	_	_	_
22-12	3978-3980	an	abstract[193]	new[193]	_	_
22-13	3981-3989	overview	abstract[193]	new[193]	_	_
22-14	3990-3992	of	abstract[193]	new[193]	_	_
22-15	3993-3996	the	abstract[193]|abstract[194]	new[193]|new[194]	_	_
22-16	3997-4003	latest	abstract[193]|abstract[194]	new[193]|new[194]	_	_
22-17	4004-4016	applications	abstract[193]|abstract[194]	new[193]|new[194]	_	_
22-18	4017-4019	of	abstract[193]|abstract[194]	new[193]|new[194]	_	_
22-19	4020-4023	EVs	abstract[193]|abstract[194]|abstract	new[193]|new[194]|giv	coref	23-28
22-20	4024-4026	as	abstract[193]|abstract[194]	new[193]|new[194]	_	_
22-21	4027-4031	drug	abstract[193]|abstract[194]|substance	new[193]|new[194]|giv	_	_
22-22	4032-4040	delivery	abstract[193]|abstract[194]|abstract	new[193]|new[194]|giv	_	_
22-23	4041-4049	vehicles	abstract[193]|abstract[194]	new[193]|new[194]	_	_
22-24	4050-4051	,	_	_	_	_
22-25	4052-4060	focusing	_	_	_	_
22-26	4061-4063	on	_	_	_	_
22-27	4064-4067	the	abstract[198]	new[198]	_	_
22-28	4068-4075	sources	abstract[198]	new[198]	_	_
22-29	4076-4084	employed	_	_	_	_
22-30	4085-4086	,	_	_	_	_
22-31	4087-4090	the	object[199]	giv[199]	_	_
22-32	4091-4100	molecules	object[199]	giv[199]	_	_
22-33	4101-4109	selected	_	_	_	_
22-34	4110-4111	,	_	_	_	_
22-35	4112-4115	and	_	_	_	_
22-36	4116-4119	the	abstract[200]	new[200]	_	_
22-37	4120-4125	final	abstract[200]	new[200]	_	_
22-38	4126-4134	intended	abstract[200]	new[200]	_	_
22-39	4135-4142	targets	abstract[200]	new[200]	_	_
22-40	4143-4144	.	_	_	_	_

#Text=In the second part of the review , we will take a step back and bring attention to the basics of one of the main pitfalls concerning EVs : the urgent need for highly pure vesicle preparation .
23-1	4145-4147	In	_	_	_	_
23-2	4148-4151	the	_	_	_	_
23-3	4152-4158	second	_	_	_	_
23-4	4159-4163	part	_	_	_	_
23-5	4164-4166	of	_	_	_	_
23-6	4167-4170	the	abstract[201]	giv[201]	_	_
23-7	4171-4177	review	abstract[201]	giv[201]	_	_
23-8	4178-4179	,	_	_	_	_
23-9	4180-4182	we	person	giv	_	_
23-10	4183-4187	will	_	_	_	_
23-11	4188-4192	take	_	_	_	_
23-12	4193-4194	a	abstract[203]	new[203]	_	_
23-13	4195-4199	step	abstract[203]	new[203]	_	_
23-14	4200-4204	back	_	_	_	_
23-15	4205-4208	and	_	_	_	_
23-16	4209-4214	bring	_	_	_	_
23-17	4215-4224	attention	abstract	new	_	_
23-18	4225-4227	to	_	_	_	_
23-19	4228-4231	the	abstract[205]	new[205]	_	_
23-20	4232-4238	basics	abstract[205]	new[205]	_	_
23-21	4239-4241	of	abstract[205]	new[205]	_	_
23-22	4242-4245	one	abstract[205]|abstract[206]	new[205]|new[206]	_	_
23-23	4246-4248	of	abstract[205]|abstract[206]	new[205]|new[206]	_	_
23-24	4249-4252	the	abstract[205]|abstract[206]|abstract[207]	new[205]|new[206]|new[207]	_	_
23-25	4253-4257	main	abstract[205]|abstract[206]|abstract[207]	new[205]|new[206]|new[207]	_	_
23-26	4258-4266	pitfalls	abstract[205]|abstract[206]|abstract[207]	new[205]|new[206]|new[207]	_	_
23-27	4267-4277	concerning	_	_	_	_
23-28	4278-4281	EVs	abstract	giv	appos	23-30[209_0]
23-29	4282-4283	:	_	_	_	_
23-30	4284-4287	the	abstract[209]	giv[209]	_	_
23-31	4288-4294	urgent	abstract[209]	giv[209]	_	_
23-32	4295-4299	need	abstract[209]	giv[209]	_	_
23-33	4300-4303	for	abstract[209]	giv[209]	_	_
23-34	4304-4310	highly	abstract[209]|abstract[211]	giv[209]|new[211]	_	_
23-35	4311-4315	pure	abstract[209]|abstract[211]	giv[209]|new[211]	_	_
23-36	4316-4323	vesicle	abstract[209]|object|abstract[211]	giv[209]|new|new[211]	_	_
23-37	4324-4335	preparation	abstract[209]|abstract[211]	giv[209]|new[211]	_	_
23-38	4336-4337	.	_	_	_	_
